BSEVivo Bio Tech LtdMediumPositive
Announced Mon, 5 Jan · 18:39 IST

please find enclosed announcement

Regulatory Product ApprovalBusiness Updates View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Vivo Bio Tech has received a Good Laboratory Practice (GLP) compliance certificate from India's National GLP Compliance Monitoring Authority (NGCMA) under the Department of Science & Technology. The certification adds three new high-value study areas: toxicity studies in dogs (including repeated dose evaluations), carcinogenicity studies for long-term safety assessment, and in vitro eye irritation/serious eye damage studies. These additions strengthen the company's ability to conduct globally acceptable non-clinical safety studies and support international regulatory filings for product registration. The company already held GLP accreditation in other areas and is now expanding its scope of services.

Likely market impact

This regulatory accreditation expands Vivo Bio Tech's service portfolio and enhances its credibility as a comprehensive GLP-compliant research testing facility, potentially opening up new business opportunities in international pharma and biotech contracts. For shareholders, this is a positive capability-enhancing milestone, though its near-term financial impact will depend on the company's ability to convert this expanded accreditation into new client wins.